JPH09124473A - Enhancer for physical fitness - Google Patents
Enhancer for physical fitnessInfo
- Publication number
- JPH09124473A JPH09124473A JP7289781A JP28978195A JPH09124473A JP H09124473 A JPH09124473 A JP H09124473A JP 7289781 A JP7289781 A JP 7289781A JP 28978195 A JP28978195 A JP 28978195A JP H09124473 A JPH09124473 A JP H09124473A
- Authority
- JP
- Japan
- Prior art keywords
- glutamine
- arginine
- physical strength
- strength enhancer
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003623 enhancer Substances 0.000 title claims abstract description 35
- 239000004475 Arginine Substances 0.000 claims abstract description 41
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 41
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000002773 nucleotide Substances 0.000 claims abstract description 34
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 34
- 239000002777 nucleoside Substances 0.000 claims abstract description 21
- 239000007787 solid Substances 0.000 claims abstract description 15
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 33
- 235000016709 nutrition Nutrition 0.000 claims description 23
- 125000003835 nucleoside group Chemical group 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 abstract description 13
- 230000002980 postoperative effect Effects 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 5
- 230000033001 locomotion Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 235000009697 arginine Nutrition 0.000 description 36
- 238000012360 testing method Methods 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 21
- 229940088594 vitamin Drugs 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 239000011782 vitamin Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 235000013350 formula milk Nutrition 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 7
- 229930064664 L-arginine Natural products 0.000 description 7
- 235000014852 L-arginine Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 235000019710 soybean protein Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 4
- 229960000367 inositol Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010068370 Glutens Proteins 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010070551 Meat Proteins Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- RAJMXAZJKUGYGW-POYBYMJQSA-N 2',3'-dideoxycytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)CC1 RAJMXAZJKUGYGW-POYBYMJQSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 101710149004 Nuclease P1 Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000228153 Penicillium citrinum Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000012888 dietary physiology Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- -1 glucose and fructose Chemical class 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000014075 nitrogen utilization Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、アルギニンを必須
成分とし、さらにグルタミン、ヌクレオチド又はヌクレ
オシドよりなる群から選択される1種以上の成分を有効
成分として含有することを特徴とする体力増強剤に関す
る。詳しくは、固形100g当たりアルギニンを3g以
上、グルタミンを3〜95g以上を含有するか、或いは
アルギニンを3g以上、グルタミンを3g以上、ヌクレ
オチド又はヌクレオシドを0.05〜1gを含有するこ
とを特徴とする体力増強剤に関する。さらにはこれらを
配合した栄養組成物に関する。本発明は、特に乳幼児、
病人、術後患者の体力増強、運動能力向上に有効であ
る。TECHNICAL FIELD The present invention relates to a physical strength-enhancing agent characterized by containing arginine as an essential ingredient, and further containing one or more kinds of ingredients selected from the group consisting of glutamine, nucleotides or nucleosides as an active ingredient. . Specifically, it is characterized by containing 3 g or more of arginine and 3 to 95 g or more of glutamine per 100 g of solid, or containing 3 g or more of arginine, 3 g or more of glutamine and 0.05 to 1 g of nucleotide or nucleoside. The present invention relates to a physical strength enhancer. Furthermore, it relates to a nutritional composition containing these. The invention is particularly suitable for infants,
It is effective in enhancing physical strength and improving exercise capacity of sick people and post-operative patients.
【0002】[0002]
【従来の技術】近年、運動生理学や栄養生理学等の分野
において、持久力や筋力、運動能力等体力の向上を目的
とした食事指導が各種スポーツ選手に行われるようにな
ってきている。例えば、蛋白質は筋力の強化に必要であ
り、脂肪や炭水化物は重要なエネルギー源である。さら
に骨強化にはカルシウム摂取が必要であり、ヘモグロビ
ンの構成成分である鉄は、酸素の体内輸送に極めて重要
な役割を果たしている。例えば、高脂肪食によってエネ
ルギー産生能が向上し、効率の良いエネルギー代謝の確
立を促すことができること、特に単価不飽和脂肪酸の有
効性が報告されており(屋代、月刊フードケミカル1993
-6、38、1993)、或いは高蛋白食摂取時に高い運動能力
が得られたとする報告(Wishrartら、 J. Physiol., Vo
l.82, p189(1934))もある。しかしながら、これらの報
告はエネルギー消費の激しい運動選手を対象としたもの
であり、消化吸収・代謝機能の低下した病人、術後患者
或いは機能の未熟な乳幼児に適応できるものではなかっ
た。2. Description of the Related Art In recent years, in the fields of exercise physiology, nutritional physiology, etc., various athletes have been given dietary guidance for the purpose of improving physical strength such as endurance, muscular strength, and exercise ability. For example, proteins are necessary for strengthening muscle strength, and fats and carbohydrates are important energy sources. In addition, calcium is required for bone strengthening, and iron, which is a constituent of hemoglobin, plays an extremely important role in transporting oxygen in the body. For example, it has been reported that high-fat diet improves energy production ability and can promote establishment of efficient energy metabolism, especially the effectiveness of monounsaturated fatty acids (Yashiro, Monthly Food Chemical 1993.
-6, 38, 1993), or that high exercise capacity was obtained when a high protein diet was taken (Wishrart et al., J. Physiol., Vo.
l.82, p189 (1934)). However, these reports were aimed at athletes with high energy consumption, and could not be applied to sick people with impaired digestive absorption and metabolic functions, postoperative patients or infants with immature functions.
【0003】体力は、例えば俊敏性や筋力などに代表さ
れる運動能力と、筋持久力や全身持久性など健康に関す
る体力に分類できるといわれている(殖田友子、小児科
診療、1994年・11号、1933)。運動能力の向上には、適
切な栄養摂取と適度な運動が必要なことはいうまでもな
いが、病人、術後患者或いは乳幼児では、運動を行えな
い場合も十分にあり得る。このような人々に対しては、
消化吸収性の良いペプチドやアミノ酸を用いた経腸栄養
剤、或いは点滴により栄養補給を行う高カロリー輸液が
栄養法として広く用いられているが、とくに体力、運動
能力の回復を意図したものではないし、乳児を対象とす
る体力増強法については、全く知られていない。しか
し、体力低下の著しい病人や術後患者、さらに乳幼児に
こそ、体力或いは運動能力を速やかに回復ないし獲得す
ることを促す体力増強剤の開発が望まれていた。Physical strength is said to be classified into athletic ability typified by agility and muscular strength, and physical strength related to health such as muscular endurance and whole body endurance (Tomoko Shikuda, Pediatric practice, 1994, No. 11, 1994). , 1933). It is needless to say that proper nutrition and proper exercise are required to improve exercise capacity, but it is quite possible that the sick person, postoperative patient or infant cannot exercise. For those people,
Enteral nutrition using peptides and amino acids with good digestion and absorption, or high-calorie infusion that supplements nutrition by infusion is widely used as a nutrition method, but it is not intended to recover physical strength and exercise capacity. , There is no known physical strength enhancement method for infants. However, there has been a demand for the development of a physical strength enhancer for promptly recovering or acquiring physical strength or athletic ability for sick people and postoperative patients with markedly decreased physical strength, and even for infants.
【0004】さらに近年、様々な成分が、免疫能や代謝
機能の調節に関与することが知られるようになり、各種
栄養剤に利用されるようになってきた。例えばアルギニ
ンは、乳児にとって準必須アミノ酸といわれる成分であ
り、体内では蛋白質が代謝されて生成する有毒なアンモ
ニアを解毒するのに必要であるほか、ポリアミンの前駆
物質としても機能すること、筋肉代謝に関与すること、
体内で窒素利用効率改善効果のあること及び免疫賦活作
用等が知られている。このような機能に着目して、アル
ギニンを配合した乳児用調製粉乳に関する特許が出願さ
れている(特開昭61-192245 号)が、アルギニンと体力
の関係は知られていない。Further, in recent years, it has become known that various components are involved in the regulation of immunocompetence and metabolic function, and they have come to be used in various nutritional supplements. For example, arginine is a component that is said to be a semi-essential amino acid for infants, is necessary to detoxify the toxic ammonia produced by the metabolism of proteins in the body, and also functions as a precursor of polyamines. To get involved,
It is known to have an effect of improving nitrogen utilization efficiency in the body, an immunostimulating effect and the like. Focusing on such a function, a patent has been filed for infant formula containing arginine (JP-A-61-192245), but the relationship between arginine and physical fitness has not been known.
【0005】又、グルタミンは骨格筋アミノ酸プールの
50〜60%、血漿アミノ酸プールの約20%を占める
アミノ酸であり、小腸上皮細胞では主要なエネルギー源
であるといわれている。又、グルタミン欠乏は腸管萎縮
の原因ともいわれ、免疫系への影響も示唆されている。
このため、近年経腸栄養剤や輸液の分野で注目され、利
用に関する技術が開示されている(特開平2-119762号公
報、特開平3-264525号公報、特開平5-236909号公報)。
さらに、スポーツ生理学の分野でもグルタミンが注目さ
れ、運動によって消費されたグリコーゲン補充や疲労時
の免疫能の回復に効果のあることが示されている(吉田
匡央、月刊フードケミカル、1994-10 、46)。しかし、
十分に運動することのできない病人や乳幼児を対象とは
していない。Glutamine is an amino acid which accounts for 50 to 60% of the skeletal muscle amino acid pool and about 20% of the plasma amino acid pool, and is said to be a major energy source in small intestinal epithelial cells. Glutamine deficiency is also said to be the cause of intestinal atrophy, and its effects on the immune system have been suggested.
Therefore, in recent years, attention has been paid to the fields of enteral nutritional supplements and infusions, and techniques relating to the use thereof have been disclosed (Japanese Patent Laid-Open Nos. 2-119762, 3-264525, and 5-236909).
Furthermore, glutamine has received attention in the field of sports physiology, and it has been shown that it is effective in supplementing glycogen consumed by exercise and in recovering immune function during fatigue (Masao Yoshida, Monthly Food Chemical, 1994-10, 46). But,
It is not intended for sick people or infants who are unable to exercise sufficiently.
【0006】又、ヌクレオチドは核酸を構成する基本単
位であり、全ての生物にとって必須な成分である。ヌク
レオチドは、シチジン、ウリジン、アデノシン、グアノ
シン、チミジン、及びイノシンの6種類のヌクレオシド
にリン酸が結合した構造を有する。体内のほとんど全て
の細胞、器官はヌクレオチドを合成する活性を有してお
り、このため長い間栄養成分としては認識されてこなか
った。しかし、近年経口摂取したヌクレオチドが体内で
脂肪酸代謝を制御したり、免疫応答に関与することが知
られるようになり、経腸栄養剤や育児用調製乳へのヌク
レオチドの配合が検討されるようになってきた。しか
し、ヌクレオチドの摂取と体力の関係に関してはこれま
で全く検討されたことはなかった。[0006] Nucleotides are basic units constituting nucleic acids and are essential components for all living organisms. Nucleotides have a structure in which phosphate is bound to six types of nucleosides, cytidine, uridine, adenosine, guanosine, thymidine, and inosine. Almost all cells and organs in the body have the activity of synthesizing nucleotides, and thus have not been recognized as nutritional components for a long time. However, in recent years it has become known that nucleotides taken orally control fatty acid metabolism in the body and are involved in the immune response, and the incorporation of nucleotides in enteral nutritional supplements and infant formula has been investigated. It's coming. However, the relationship between nucleotide intake and physical fitness has never been studied.
【0007】[0007]
【発明が解決しようとする課題】上述の状況に鑑み、本
発明者らは近年特殊栄養成分として注目されてきている
各種栄養素に着目して鋭意研究の結果、一般人や病人、
術後患者さらに乳幼児に対してその消化、吸収、代謝能
に負担をかけることなく、その体力の回復あるいは獲得
を可能とする体力増強剤を見出すに至った。即ち、アル
ギニンを必須成分とし、さらにグルタミン、ヌクレオチ
ド又はヌクレオシドよりなる群から選択される1種以上
の成分を組み合わせることにより、前述の体力増強剤を
見出すに至った。従って本発明は、アルギニンを必須成
分とし、さらにグルタミン、ヌクレオチド又はヌクレオ
シドよりなる群から選択される1種以上の成分からなる
ことを特徴とする体力増強剤を提供することを課題とす
る。In view of the above situation, the present inventors have focused their attention on various nutrients that have been attracting attention as special nutritional ingredients in recent years, and as a result of diligent research, the general public and the sick person,
We have found a physical strength enhancer that can recover or acquire physical strength of postoperative patients and infants without imposing a burden on their digestion, absorption and metabolic ability. That is, the above-mentioned physical strength enhancer was found by combining arginine as an essential component and further combining one or more components selected from the group consisting of glutamine, nucleotides or nucleosides. Therefore, an object of the present invention is to provide a physical strength enhancer characterized by comprising arginine as an essential component and further comprising one or more components selected from the group consisting of glutamine, nucleotides or nucleosides.
【0008】[0008]
【発明を解決するための手段】本発明は、アルギニンを
必須成分とし、さらにグルタミン、ヌクレオチド又はヌ
クレオシドよりなる群から選択される1種以上の成分を
有効成分として含有することを特徴とする体力増強剤に
関する。さらには、これを配合した栄養組成物に関す
る。The present invention is characterized by containing arginine as an essential ingredient and further containing one or more kinds of ingredients selected from the group consisting of glutamine, nucleotides or nucleosides as an active ingredient. Regarding agents. Furthermore, it relates to a nutritional composition containing the same.
【0009】本発明の体力増強剤は、対象である病人、
術後患者、乳幼児が摂取しやすい形態であれば良い。例
えば経口投与の時は錠剤、カプセル剤、顆粒剤、散剤、
ドリンク剤等が挙げられる。この時、必要に応じて通常
製剤に用いられる製剤成分、例えば賦形剤、結合剤、滑
沢剤、乳化剤等を加えても良い。又、単独の製剤の形態
ではなく、栄養組成物、例えば各種病態食、経口・経腸
栄養剤、調製乳、飲料或いは離乳食等に本発明体力増強
剤を配合しても良い。調製乳として、例えば乳児用調製
粉乳、フォローアップミルク、タンパク質分解乳、特殊
栄養調製乳等が挙げられる。栄養組成物の組成は、本発
明品である体力増強剤成分の他に、蛋白質、脂質、糖
質、ビタミン及びミネラル類を主成分とする。この場合
も形態にはこだわらず、摂取しやすい形態であれば、固
形、粉末、液体、ゲル状、スラリー状等のいずれであっ
ても良い。この時、栄養組成物の固形あたり、上記体力
増強剤を0.1〜10重量%配合するのが好適である。The physical strength-enhancing agent of the present invention is a sick person,
Any form that can be easily taken by postoperative patients and infants may be used. For example, for oral administration, tablets, capsules, granules, powders,
Examples include drinks. At this time, if necessary, formulation components usually used in formulations such as excipients, binders, lubricants, emulsifiers and the like may be added. Further, the physical strength enhancer of the present invention may be blended not in the form of a single preparation but in nutritional compositions such as various pathological diets, oral / enteral nutritional supplements, modified milk, beverages or baby foods. Examples of the modified milk include infant formula, follow-up milk, proteolytic milk, and special nutritional formula. The composition of the nutritional composition contains proteins, lipids, sugars, vitamins and minerals as main components in addition to the physical strength enhancer component of the present invention. In this case as well, regardless of the form, any form such as solid, powder, liquid, gel, or slurry may be used as long as it is an easily ingested form. At this time, it is preferable to add 0.1 to 10% by weight of the physical strength enhancer per solid of the nutritional composition.
【0010】本発明の有効成分であるアルギニンは、遊
離型であるL−アルギニンの他に、L−アルギニンが主
たるアミノ酸であるペプチド型アルギニン、或いはアル
ギニン含量の多い蛋白質、例えば分離大豆蛋白質であっ
ても良く、さらにはアルギニン含量の高い蛋白質を加水
分解して得られるペプチド型アルギニンであっても良
い。又これらの組み合わせでも良い。グルタミンは、遊
離型のL−グルタミンの他にグルタミンが主たるアミノ
酸を構成するペプチド型グルタミン或いはグルテン等グ
ルタミンを多量に含有する蛋白質を加水分解して得られ
るペプチド型グルタミンであっても良く、さらにこれら
の組み合わせであっても良い。ヌクレオチド或いはヌク
レオシドは、それぞれ遊離型であっても、ナトリウム或
いはカリウム塩であってもかまわない。ヌクレオチドと
ヌクレオシドの間には、活性の差は殆どなく、どちらを
用いても良い。体力の増強には、上記成分のうちアルギ
ニンを必須成分とし、これにグルタミン、ヌクレオチド
或いはヌクレオシドから選ばれる1種類以上の成分を同
時に投与することが必要である。本発明品の1日当たり
の投与量としては、成人の場合1〜10g、乳幼児の場
合0.1〜2gが望ましい。又、本発明品は1日1回規
定量を経口的に投与しても良く、又は食間、食前、食後
を問わず数回に分けて投与しても良い。The arginine which is an active ingredient of the present invention is, in addition to L-arginine which is a free form, peptide-type arginine whose main amino acid is L-arginine, or a protein having a high arginine content such as isolated soybean protein. Further, it may be a peptide type arginine obtained by hydrolyzing a protein having a high arginine content. Also, a combination of these may be used. Glutamine may be peptide glutamine which forms a major amino acid in addition to free L-glutamine, or peptide glutamine obtained by hydrolyzing a protein containing a large amount of glutamine such as gluten. May be a combination of. The nucleotide or nucleoside may be in a free form or a sodium or potassium salt, respectively. There is almost no difference in activity between nucleotides and nucleosides, and either one may be used. In order to enhance physical strength, it is necessary to make arginine an essential component among the above components, and to administer at the same time one or more components selected from glutamine, nucleotides or nucleosides. The daily dose of the product of the present invention is preferably 1 to 10 g for adults and 0.1 to 2 g for infants. In addition, the product of the present invention may be orally administered once a day in a prescribed amount, or may be administered in several divided doses between meals, before meals and after meals.
【0011】本発明体力増強剤は、例えば乳児用調製乳
や経腸栄養剤等の栄養組成物に添加しても、何ら問題は
ない。本発明体力増強剤を配合した栄養組成物を構成す
る蛋白質は、脱脂乳、カゼイン、チーズホエー、ホエー
蛋白質濃縮物(WPC)、ホエー蛋白質分離物(WP
I)等の乳蛋白質や、これらの分画物であるαS−カゼ
イン、β−カゼイン、α−ラクトアルブミン及びβ−ラ
クトグロブリン等であり、又、卵黄蛋白質、卵白蛋白
質、オボアルブミン等の卵蛋白質、或いは脱脂大豆蛋白
質、分離大豆蛋白質、濃縮大豆蛋白質等の大豆蛋白質を
挙げることができる。或いは小麦グルテン、魚肉蛋白
質、畜肉蛋白質、コラーゲン等の蛋白質を用いても良
い。さらには、上記した蛋白質の分画物や酸或いは酵素
で処理して調製したペプチド或いは遊離アミノ酸であっ
ても良い。遊離アミノ酸は窒素源としての他に特定の生
理作用を付与するために用いることもでき、その例とし
て、タウリン、シスチン、システイン等を挙げることが
できる。蛋白質やペプチド、遊離アミノ酸の配合量は、
固形分あたり5〜30重量%が適当である。糖質として
は、でんぷん,可溶性多糖類、デキストリン、しょ糖、
乳糖、麦芽糖、ブドウ糖や果糖等の単糖類、さらにガラ
クトオリゴ糖、フラクトオリゴ糖、ラクチュロース等の
オリゴ糖を挙げることができ、これらの糖類の中から1
種類以上を配合する。糖質の配合量は、栄養組成物の固
形分当たり30〜80重量%であることが望ましい。
又、用途によってはアスパルテーム等の人工甘味料を用
いることもでき、この場合の配合量は固形分当たり0.
05〜1.0重量%が適当である。脂質としては、乳脂
肪、ラード、牛脂及び魚油等の動物性油脂、大豆油、菜
種油、コーン油、ヤシ油、パーム油、パーム核油、サフ
ラワー油、エゴマ油、アマニ油、月見草油、中鎖脂肪酸
トリグリセリド(MCT)及び綿実油等の植物性油脂、
さらにはこれらの分別油、水添油、エステル交換油のい
ずれか1種以上を用いることができる。脂質は栄養組成
物の固形当たり40重量%以下の配合が好ましい。There is no problem even if the physical strength enhancer of the present invention is added to nutritional compositions such as infant formula and enteral nutritional supplements. The protein constituting the nutritional composition containing the physical strength enhancer of the present invention is skim milk, casein, cheese whey, whey protein concentrate (WPC), whey protein isolate (WP).
Milk proteins such as I) and their fractions αS-casein, β-casein, α-lactalbumin and β-lactoglobulin, and egg proteins such as egg yolk protein, egg white protein and ovalbumin. Alternatively, soybean proteins such as defatted soybean protein, isolated soybean protein and concentrated soybean protein can be mentioned. Alternatively, proteins such as wheat gluten, fish meat protein, animal meat protein and collagen may be used. Further, it may be a peptide fraction or a free amino acid prepared by treating the above-mentioned protein fraction, acid or enzyme. The free amino acid can be used not only as a nitrogen source but also for imparting a specific physiological action, and examples thereof include taurine, cystine, cysteine and the like. The amount of protein, peptide, and free amino acid compounded is
5 to 30% by weight per solid content is suitable. As sugars, starch, soluble polysaccharides, dextrin, sucrose,
Lactose, maltose, monosaccharides such as glucose and fructose, and oligosaccharides such as galactooligosaccharide, fructooligosaccharide and lactulose can be mentioned.
Mix more than one kind. The sugar content is preferably 30 to 80% by weight based on the solid content of the nutritional composition.
In addition, an artificial sweetener such as aspartame may be used depending on the application, and the blending amount in this case is 0.
05 to 1.0% by weight is suitable. As the lipid, milk fat, lard, animal fats and oils such as beef tallow and fish oil, soybean oil, rapeseed oil, corn oil, coconut oil, palm oil, palm kernel oil, safflower oil, perilla oil, linseed oil, evening primrose oil, medium Vegetable oils and fats such as chain fatty acid triglyceride (MCT) and cottonseed oil,
Furthermore, any one or more of these fractionated oils, hydrogenated oils, and transesterified oils can be used. The lipid content is preferably 40% by weight or less per solid of the nutritional composition.
【0012】ビタミン及びミネラルについては、「日本
国際酪農連盟発行、乳幼児食品を含む特殊用途食品のCO
DEX 規格及び関連衛生作業規則、CAC/VOL.IX- 第1版及
びSupplement 1,2,3,4 (1993) 」、「食品と科学社発
行、1993年版指定品目食品添加物便覧(改訂第31版)
(1993)」及び「食品と科学社発行、届け出制食品添加
物・食品素材天然物便覧(第12版)(1992)」に記載さ
れているビタミン類及びミネラル類のうち栄養組成物に
使用可能なものの中から1種以上を用いることができ
る。ビタミン類として、例えばビタミンA、B類、C、
D、E、K、葉酸、パントテン酸、β−カロチン、ニコ
チン酸アミド、カルニチン、コリン、イノシトール、ビ
オチン等が挙げられ、これらの配合量は栄養組成物の固
形分100g当たり10mg〜5gが好ましい。ミネラ
ル類として、カルシウム、マグネシウム、カリウム、ナ
トリウム、鉄、銅、亜鉛、リン、塩素、マンガン、セレ
ン、ヨウ素等が挙げられ、これらの配合量は栄養組成物
100g当たり1mg〜5gが好ましい。Regarding vitamins and minerals, refer to "CO of special purpose foods including infant foods, issued by Japan International Dairy Federation.
DEX Standards and Related Sanitary Work Regulations, CAC / VOL.IX- 1st Edition and Supplements 1,2,3,4 (1993) "," Published by Food and Science Co., 1993 Edition Specified Food Additives Handbook (Revised 31 Edition)
(1993) ”and“ Food and Scientific Publishing, Notification System Food Additives / Food Materials Natural Products Handbook (12th Edition) (1992) ”can be used for nutritional composition of vitamins and minerals. One or more of these can be used. Examples of vitamins include vitamins A, B, C,
D, E, K, folic acid, pantothenic acid, β-carotene, nicotinic acid amide, carnitine, choline, inositol, biotin and the like can be mentioned, and the compounding amount thereof is preferably 10 mg to 5 g per 100 g of the solid content of the nutritional composition. Examples of minerals include calcium, magnesium, potassium, sodium, iron, copper, zinc, phosphorus, chlorine, manganese, selenium and iodine, and the amount of these is preferably 1 mg to 5 g per 100 g of the nutritional composition.
【0013】[0013]
【実施例】以下の実施例により本発明をより詳細に説明
するが、本発明はこれらによって何ら限定されるもので
はない。The present invention will be described in more detail with reference to the following examples, which should not be construed as limiting the invention thereto.
【0014】[0014]
【実施例1】本発明体力増強剤の調製(錠剤) L−アルギニン50g、L−グルタミン50g(ともに
協和発酵社)、及び5’−シチジン一リン酸、5’−ウ
リジン一リン酸、5’−アデノシン一リン酸、5’−グ
アノシン一リン酸、5’−イノシン一リン酸(いづれも
ヤマサ社)を混合して調製したヌクレオチド混合物1g
を均一に混合し、これを直接打錠剤法で錠剤とした。こ
の時、1錠当たりの重量は1gであった。[Example 1] Preparation of physical strength enhancer of the present invention (tablet) L-arginine 50 g, L-glutamine 50 g (both Kyowa Hakko Co., Ltd.), and 5'-cytidine monophosphate, 5'-uridine monophosphate, 5 ' 1 g of a nucleotide mixture prepared by mixing -adenosine monophosphate, 5'-guanosine monophosphate, 5'-inosin monophosphate (both Yamasa)
Were uniformly mixed, and tablets were obtained by the direct tableting method. At this time, the weight per tablet was 1 g.
【0015】[0015]
【実施例2】本発明体力増強剤の調製(散剤) 小麦グルテン200g(ナカライテスク社)をエタノー
ルに溶解し、攪拌しながら1%酢酸中に懸濁した。この
懸濁液にモルシン(プロテアーゼタイプVIII、シグマ
社)を37℃で24時間反応させ、さらにアクチナーゼ
(科研製薬社)を37℃で24時間反応させた。この反
応によって生成した遊離アミノ酸を分画分子量500の
限外濾過膜(ダイアフローメンブレンYC05、アミコ
ン社)で処理することにより除去し、グルタミン含量4
0重量%のグルタミンペプチド142gを得た。これに
L−アルギニン50g(協和発酵社)、及び実施例1と
同様に調製したヌクレオチド混合物1gを均一に混合
し、粒径を350μm以下に調製して散剤とした。[Example 2] Preparation of physical strength enhancer of the present invention (powder) 200 g of wheat gluten (Nacalai Tesque) was dissolved in ethanol and suspended in 1% acetic acid while stirring. Morcine (Protease Type VIII, Sigma) was reacted with this suspension at 37 ° C. for 24 hours, and actinase (Kaken Pharmaceutical Co., Ltd.) was further reacted at 37 ° C. for 24 hours. The free amino acid produced by this reaction was removed by treatment with an ultrafiltration membrane having a molecular weight cutoff of 500 (Diaflow Membrane YC05, Amicon) to give a glutamine content of 4
142 g of 0% by weight of glutamine peptide was obtained. 50 g of L-arginine (Kyowa Hakko Co., Ltd.) and 1 g of the nucleotide mixture prepared in the same manner as in Example 1 were uniformly mixed with the mixture to prepare a powder having a particle size of 350 μm or less.
【0016】[0016]
【実施例3】本発明体力増強剤の調製(調製粉乳) 脱脂乳5.04kgに乳清タンパク質濃縮物(WPC、
日本プロテン社)を158g及び乳糖924gを添加し
た。これに水溶性ビタミン類(ビタミンB1 、B2 、B
6 、B12、C、ナイアシン、葉酸、パントテン酸、ビオ
チン、コリン、イノシトール)及びミネラル類(炭酸カ
ルシウム、塩化カリウム、硫酸マグネシウム、クエン酸
第一鉄ナトリウム、硫酸銅、硫酸亜鉛)をそれぞれ7.
5g添加溶解し、さらに脂溶性ビタミン類(ビタミン
A、D、E、K、β−カロチン)を溶解した調製脂肪5
78gを加えて混合した。これを均質化し、常法に従い
殺菌処理をした後、濃縮、乾燥して調製粉乳2.1kg
を得た。これに、L−アルギニン50g、L−グルタミ
ン50g(ともに協和発酵社)、及び実施例1と同様に
調製したヌクレオチド混合物1gの混合物21gを均一
に混合し、体力増強成分含有調製粉乳2.1kgを得
た。[Example 3] Preparation of physical strength enhancer of the present invention (prepared milk powder) 5.04 kg of skim milk was added to whey protein concentrate (WPC,
158 g of Japan Proten Co., Ltd.) and 924 g of lactose were added. In addition to this, water-soluble vitamins (vitamins B 1 , B 2 , B
6 , B 12 , C, niacin, folic acid, pantothenic acid, biotin, choline, inositol) and minerals (calcium carbonate, potassium chloride, magnesium sulfate, ferrous sodium citrate, copper sulfate, zinc sulfate) respectively.
Prepared fat 5 in which 5 g was added and dissolved, and further fat-soluble vitamins (vitamins A, D, E, K, β-carotene) were dissolved
78g was added and mixed. It is homogenized, sterilized according to the usual method, then concentrated and dried to formulate milk powder 2.1 kg.
I got To this, 50 g of L-arginine, 50 g of L-glutamine (both Kyowa Hakko Co., Ltd.), and 21 g of a mixture of 1 g of the nucleotide mixture prepared in the same manner as in Example 1 were uniformly mixed, and 2.1 kg of a formula powder containing a physical strength-enhancing component was prepared. Obtained.
【0017】[0017]
【実施例4】本発明体力増強剤の調製(育児用調製粉乳) 乳清タンパク質濃縮物(WPC、日本プロテン社)88
0g及び乳糖5.2kgを20kgの温湯に溶解し、さ
らに牛乳7.5kg及びカゼイン490gを所定のアル
カリに溶解した溶液を加えた。これに水溶性ビタミン類
(ビタミンB1、B 2 、B6 、B12、C、ナイアシン、
葉酸、パントテン酸、ビオチン、コリン、イノシトー
ル)及びミネラル類(炭酸カルシウム、塩化カリウム、
硫酸マグネシウム、クエン酸第一鉄ナトリウム、硫酸
銅、硫酸亜鉛)をそれぞれ7.5g添加溶解し、さらに
脂溶性ビタミン類(ビタミンA、D、E、K、β−カロ
チン)を溶解した調製脂肪2.5kgを加えて混合し
た。これを均質化し、常法に従って殺菌処理した後、濃
縮、乾燥して育児用調製粉乳10kgを得た。これに、
L−アルギニン及び実施例2で調製したグルタミンペプ
チドの1:1混合物100gを均一に混合し、体力増強
成分含有調製粉乳10.0kgを得た。Example 4 Preparation of Physical Strength Enhancer of the Present Invention (Powdered Milk Powder) Whey Protein Concentrate (WPC, Nippon Proten) 88
0 g and lactose (5.2 kg) were dissolved in 20 kg of warm water, and a solution of milk (7.5 kg) and casein (490 g) dissolved in a predetermined alkali was added. Water soluble vitamins (vitamins B 1, B 2 , B 6 , B 12 , C, niacin,
Folic acid, pantothenic acid, biotin, choline, inositol) and minerals (calcium carbonate, potassium chloride,
Prepared fat 2 in which 7.5 g of magnesium sulfate, sodium ferrous citrate, copper sulfate and zinc sulfate were added and dissolved, and further fat-soluble vitamins (vitamins A, D, E, K, β-carotene) were dissolved 0.5 kg was added and mixed. This was homogenized, sterilized by a conventional method, concentrated and dried to obtain 10 kg of infant formula. to this,
100 g of a 1: 1 mixture of L-arginine and the glutamine peptide prepared in Example 2 was uniformly mixed to obtain 10.0 kg of a formula powder containing a strength-enhancing component.
【0018】[0018]
【実施例5】本発明体力増強剤の調製(育児用調製粉乳・2) 酵母RNA(和光純薬社)100gを温水に溶解し、こ
れにヌクレアーゼP1(Penicillium citrinum由来、和
光純薬社)を添加して37℃で24時間反応させた後、
さらにアデニルデアミナーゼ(Aspergillus sp. 、シグ
マ社)を37℃で6時間反応させた。これを分画分子量
500の限外濾過膜(ダイアフローメンブレンYC0
5、アミコン社)により未反応のRNAを除去し、ヌク
レオチド72gを得た。このヌクレオチド10gを大豆
ペプチド(アルギニン含量7.7%、不二製油社)50
0g及び実施例2で調製したグルタミンペプチド490
gと均一に混合し、体力増強剤1kgを得た。これとは
別に、乳清タンパク質濃縮物(WPC、日本プロテン
社)8.4kgと乳糖47kgを300kgの温湯に溶
解し、さらにカゼイン7.1kgを所定量のアルカリに
溶解した溶液を加えた。これに水溶性ビタミン類(ビタ
ミンB1 、B2 、B6 、B12、C、ナイアシン、葉酸、
パントテン酸、ビオチン、コリン、イノシトール)及び
ミネラル類(炭酸カルシウム、塩化カリウム、硫酸マグ
ネシウム、クエン酸第一鉄ナトリウム、硫酸銅、硫酸亜
鉛)をそれぞれ1kg添加溶解し、さらに脂溶性ビタミ
ン類(ビタミンA、D、E、K、β−カロチン)を溶解
した調製脂肪27.4kg、及び先に調製した体力増強
剤1kgを加えて混合した。これを均質化し、常法に従
って殺菌処理した後、濃縮、乾燥して育児用調製粉乳1
00kgを得た。[Example 5] Preparation of the physical strength enhancer of the present invention (milk powder for childcare-2) Yeast RNA (Wako Pure Chemical Industries, Ltd.) 100 g was dissolved in warm water, and nuclease P1 (Penicillium citrinum origin, Wako Pure Chemical Industries, Ltd.) was added thereto. After adding and reacting at 37 ° C. for 24 hours,
Furthermore, adenyl deaminase (Aspergillus sp., Sigma) was reacted at 37 ° C. for 6 hours. An ultrafiltration membrane with a molecular weight cutoff of 500 (diaflow membrane YC0
5, unreacted RNA was removed by Amicon) to obtain 72 g of nucleotide. Soy peptide (arginine content 7.7%, Fuji Oil Co., Ltd.) 50 g
0 g and the glutamine peptide 490 prepared in Example 2
g to obtain a physical strength enhancer (1 kg). Separately, 8.4 kg of whey protein concentrate (WPC, Nippon Proten Co., Ltd.) and 47 kg of lactose were dissolved in 300 kg of warm water, and a solution of 7.1 kg of casein in a predetermined amount of alkali was added. Water soluble vitamins (vitamins B 1 , B 2 , B 6 , B 12 , C, niacin, folic acid,
1 kg of pantothenic acid, biotin, choline, inositol) and minerals (calcium carbonate, potassium chloride, magnesium sulfate, sodium ferrous citrate, copper sulfate, zinc sulfate) were added and dissolved, and fat-soluble vitamins (vitamin A) , D, E, K, β-carotene) was dissolved in 27.4 kg of the prepared fat, and 1 kg of the physical strength enhancer prepared above was added and mixed. This is homogenized, sterilized according to the usual method, then concentrated and dried to prepare infant formula 1
00 kg was obtained.
【0019】[0019]
【実施例6】体力増強試験・1 試験用飼料として、カゼイン25%、コーンスターチ5
3.5%、セルロースパウダー8.0%、しょ糖3.0
%、大豆油6.0%、AIN−76組成(J. Nutr., Vo
l.107, p1340 (1977) )によるミネラル混合物3.5
%、ビタミン混合物1.0%の組成の飼料を調製した。
これとは別に、L−アルギニン、L−グルタミン、及び
ヌクレオチドを用いて体力増強剤を調製した。体力増強
剤の各組成を表1に示す。これらに賦形剤としてデキス
トリンを加え、それぞれ100gとなるように調製し
た。又、対照として賦形剤のみの製剤も用意した。尚、
投与時に都度これを水に溶解して用いた。[Example 6] Physical strength enhancement test 1 As a test feed, casein 25%, corn starch 5
3.5%, cellulose powder 8.0%, sucrose 3.0
%, Soybean oil 6.0%, AIN-76 composition (J. Nutr., Vo
l.107, p1340 (1977)) Mineral mixture 3.5
%, A mixture of vitamins 1.0% was prepared.
Separately from this, a physical strength enhancer was prepared using L-arginine, L-glutamine, and nucleotides. Table 1 shows each composition of the physical strength enhancer. Dextrin was added to these as an excipient to prepare 100 g of each. As a control, a preparation containing only an excipient was also prepared. still,
This was dissolved in water and used at each administration.
【0020】[0020]
【表1】 試験剤1:アルギニン1g 試験剤2:アルギニン3g 試験剤3:アルギニン95g 試験剤4:グルタミン95g 試験剤5:ヌクレオチド1.0g 試験剤6:アルギニン3g+グルタミン95g 試験剤7:アルギニン3g+ヌクレオチド1.0g 試験剤8:アルギニン3g+グルタミン3g+ヌクレオ
チド0.05gTable 1 Test agent 1: Arginine 1 g Test agent 2: Arginine 3 g Test agent 3: Arginine 95 g Test agent 4: Glutamine 95 g Test agent 5: Nucleotides 1.0 g Test agent 6: Arginine 3 g + glutamine 95 g Test agent 7: Arginine 3 g + Nucleotides 1.0 g Test Agent 8: Arginine 3 g + Glutamine 3 g + Nucleotides 0.05 g
【0021】実験動物として、3週齢のSD系雄ラット
(体重35〜45g)を用い、各群5匹ずつ5日間の予
備飼育後、上記飼料を自由摂取させ28日間飼育した。
この間、毎日体重1kg当たり1gの割合で、上記の体
力増強剤を強制的に経口投与した。運動試験は、田中ら
の方法(体育学研究、33(2) 、155 、1988)に準じて水
泳試験により行った。試験開始21日目より連日、1 日
10分間の水泳運動を行い、ラットを水に慣らし、試験
開始28日目にオールアウト試験を実施した。これは、
ラットの尾に体重の4%に相当する重りをつけて水泳を
行わせ、水面下に10秒間沈んだ時点をオールアウトと
して、水泳開始からオールアウトまでの時間を測定し、
運動能力を判定する方法である。結果を図1に示す。As experimental animals, 3-week-old male SD rats (body weight: 35 to 45 g) were preliminarily reared for 5 days with 5 animals in each group, and then fed ad libitum for 28 days.
During this period, the above-mentioned physical strength enhancer was forcibly orally administered daily at a rate of 1 g per 1 kg of body weight. The exercise test was carried out by a swimming test according to the method of Tanaka et al. (Study on Physical Education, 33 (2), 155, 1988). From the 21st day after the start of the test, daily swimming exercises were carried out for 10 minutes, the rats were acclimated to water, and the all-out test was carried out on the 28th day of the test. this is,
A weight corresponding to 4% of the body weight was applied to the tail of the rat to perform swimming, and the time when it sank below the surface for 10 seconds was taken as all-out, and the time from the start of swimming to all-out was measured.
This is a method of determining athletic ability. The results are shown in FIG.
【0022】[0022]
【図1】FIG.
【0023】この結果より、アルギニン単独でも体力増
強に効果が認められたが、アルギニンとグルタミン、ア
ルギニンとヌクレオチド、又はアルギニン、グルタミ
ン、ヌクレオチドを投与した場合にさらに効果のあるこ
とが示された。しかし、グルタミン、ヌクレオチドを単
独で投与しても、体力増強効果は認められなかった。From these results, it was shown that arginine alone was effective in enhancing the physical strength, but it was shown to be more effective when arginine and glutamine, arginine and nucleotide, or arginine, glutamine and nucleotide were administered. However, even if glutamine and nucleotide were administered alone, the physical strength enhancing effect was not observed.
【0024】[0024]
【実施例7】体力増強試験・2 表2に示す組成の体力増強剤に増量剤としてしょ糖を添
加し100gとしたものを、実施例6の試験用飼料に1
重量%の割合で混合し、それぞれを試験食1〜8とし
た。又、対象として基本飼料に試験剤調製の際に増量剤
として用いたしょ糖を1重量%添加した飼料を用いた。
実験動物として、2週齢のSD系雄ラット(体重22〜
32g)を用いた。生後17日目に母親と離して早期離
乳させ、各試験食及び水を自由摂取させて、4週間飼育
した。試験開始28日目に、エーテル麻酔下に後肢のヒ
ラメ筋と前肢の長橈側手根伸筋を採取し、後大静脈より
採血した。筋肉重量を測定するとともに、血液中のヘモ
グロビン濃度をHemoglobin Test Wako(和光純薬社)に
より測定した。ヒラメ筋並びに長橈側手根伸筋の重量の
体重に対する比率を図2及び3に、血液中ヘモグロビン
濃度を図4に示す。Example 7 Physical Strength Enhancement Test 2 A physical strength enhancer having the composition shown in Table 2 was supplemented with sucrose as a bulking agent to give 100 g, which was added to the test feed of Example 1 as 1
The mixture was mixed at a weight percentage, and each of them was used as test meals 1 to 8. In addition, as a target, a feed containing 1% by weight of sucrose used as a bulking agent in preparing a test agent was used as a basic feed.
Two-week-old SD male rats (body weight 22-
32g) was used. On the 17th day after birth, the animals were weaned early, apart from their mothers, allowed to freely ingest each test meal and water, and bred for 4 weeks. On the 28th day from the start of the test, the soleus muscle of the hind limb and the extensor carpi radialis longus of the forelimb were collected under ether anesthesia, and blood was collected from the posterior vena cava. The muscle weight was measured and the hemoglobin concentration in blood was measured by Hemoglobin Test Wako (Wako Pure Chemical Industries, Ltd.). The ratio of the weight of the soleus muscle and the extensor carpi radialis to the body weight is shown in FIGS. 2 and 3, and the hemoglobin concentration in blood is shown in FIG.
【0025】[0025]
【表2】 試験剤1:アルギニン1g 試験剤2:アルギニン3g 試験剤3:アルギニン3g+グルタミン3g 試験剤4:アルギニン3g+グルタミン95g 試験剤5:アルギニン3g+ヌクレオシド0.05g 試験剤6:アルギニン3g+ヌクレオシド1g 試験剤7:アルギニン1g+グルタミン95g+ヌクレ
オシド1g 試験剤8:アルギニン3g+グルタミン3g+ヌクレオ
シド0.05g[Table 2] Test agent 1: Arginine 1 g Test agent 2: Arginine 3 g Test agent 3: Arginine 3 g + glutamine 3 g Test agent 4: Arginine 3 g + glutamine 95 g Test agent 5: Arginine 3 g + nucleoside 0.05 g Test agent 6: Arginine 3 g + nucleoside 1 g Test Agent 7: Arginine 1 g + Glutamine 95 g + Nucleoside 1 g Test Agent 8: Arginine 3 g + Glutamine 3 g + Nucleoside 0.05 g
【0026】[0026]
【図2】FIG. 2
【0027】[0027]
【図3】FIG. 3
【0028】[0028]
【図4】FIG. 4
【0029】この結果から、試験食1及び試験食7を除
く各試験食で、とくにトレーニングを行わなくとも、筋
肉量が増加していることが示された。又、これらの群で
は血液中のヘモグロビン値もコントロール食群よりも高
いことが示された。即ち、アルギニン、グルタミン、ヌ
クレオチド或いはヌクレオシドを経口的、連続的に摂取
することで、蛋白質代謝が改善されて筋肉量が増え、さ
らに消化管からの鉄吸収能が向上することによって血液
中のヘモグロビンが増え、体力ことに全身持久力が向上
するということが示唆された。From these results, it was shown that each test meal except test meal 1 and test meal 7 showed an increase in muscle mass without any particular training. It was also shown that the hemoglobin level in blood was higher in these groups than in the control diet group. That is, by orally and continuously ingesting arginine, glutamine, nucleotides or nucleosides, protein metabolism is improved, muscle mass is increased, and further iron absorption from the digestive tract is improved, so that hemoglobin in blood is increased. It was suggested that the physical strength increased and the endurance of the whole body improved.
【0030】[0030]
【発明の効果】これらの結果から、本発明によりアルギ
ニンを必須成分とし、さらにグルタミン、ヌクレオチド
又はヌクレオシドよりなる群から選択される1種以上の
成分を有効成分として含有することを特徴とする体力増
強剤が提供される。さらには、これを配合した体力増強
栄養組成物が提供される。本発明体力増強剤は、特に乳
幼児、病人、術後患者の体力増強、運動能力向上に有効
である。From the above results, according to the present invention, arginine is contained as an essential ingredient, and further, one or more kinds of ingredients selected from the group consisting of glutamine, nucleotides or nucleosides are contained as an active ingredient. An agent is provided. Furthermore, a physical strength-enhancing nutritional composition containing the same is provided. The physical strength enhancer of the present invention is particularly effective for increasing physical strength and improving exercise capacity of infants, sick people, and postoperative patients.
【図1】 本発明体力増強剤による、ラットの水泳時間
に対する効果を示す。FIG. 1 shows the effect of the physical strength enhancer of the present invention on swimming time in rats.
【図2】 本発明体力増強剤を配合した栄養組成物によ
る、ラットの後肢ヒラメ筋に対する効果を示す。FIG. 2 shows the effect of the nutritional composition containing the physical strength enhancer of the present invention on the soleus muscle of the hind limb of rats.
【図3】 本発明体力増強剤を配合した栄養組成物によ
る、ラットの前肢長橈側手根伸筋に対する効果を示す。FIG. 3 shows the effect of the nutritional composition containing the physical strength enhancer of the present invention on the extensor carpi radialis longus of the forelimb in rats.
【図4】 本発明体力増強剤を配合した栄養組成物によ
る、ラットの血中ヘモグロビン濃度に対する効果を示
す。FIG. 4 shows the effect of a nutritional composition containing the physical strength enhancer of the present invention on blood hemoglobin concentration in rats.
Claims (6)
タミン、ヌクレオチド又はヌクレオシドよりなる群から
選択される1種以上の成分を有効成分として含有するこ
とを特徴とする体力増強剤。1. A physical strength enhancer, which comprises arginine as an essential component, and further contains, as an active ingredient, one or more components selected from the group consisting of glutamine, nucleotides and nucleosides.
5g含有することを特徴とする、請求項1記載の体力増
強剤。2. Arginine of 3 to 9 per 100 g of solid.
The physical strength enhancer according to claim 1, which contains 5 g.
上含有することを特徴とする、請求項2記載の体力増強
剤。3. The physical strength enhancer according to claim 2, which contains 3 g or more of glutamine per 100 g of solid.
クレオシドを0.05g以上含有することを特徴とす
る、請求項3記載の体力増強剤。4. The physical strength enhancer according to claim 3, which contains 0.05 g or more of nucleotides or nucleosides per 100 g of solid.
上、グルタミンを3〜95g、ヌクレオチド又はヌクレ
オシドを0.05g〜1gを含有することを特徴とす
る、請求項1記載の体力増強剤。5. The physical strength enhancer according to claim 1, which contains 3 g or more of arginine, 3 to 95 g of glutamine, and 0.05 g to 1 g of nucleotide or nucleoside per 100 g of solid.
養組成物。6. A nutritional composition containing the physical strength enhancer according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28978195A JP4526047B2 (en) | 1995-11-08 | 1995-11-08 | Strength enhancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28978195A JP4526047B2 (en) | 1995-11-08 | 1995-11-08 | Strength enhancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09124473A true JPH09124473A (en) | 1997-05-13 |
JP4526047B2 JP4526047B2 (en) | 2010-08-18 |
Family
ID=17747688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP28978195A Expired - Fee Related JP4526047B2 (en) | 1995-11-08 | 1995-11-08 | Strength enhancer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4526047B2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2782270A1 (en) * | 1998-08-12 | 2000-02-18 | Michel Seman | Use of adenosine and adenylic nucleotides to improve muscular effort in sports and in immobilized and bedridden |
WO2000032202A1 (en) * | 1998-12-02 | 2000-06-08 | Philippe Gorny | Method for obtaining and using a combination of a purine and a nitrogen monoxide donor for preventing or treating sexual dysfunction |
JP2003510059A (en) * | 1999-09-29 | 2003-03-18 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | Composition comprising casein protein and whey protein |
WO2008149802A1 (en) | 2007-05-31 | 2008-12-11 | Suntory Holdings Limited | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient |
WO2009038095A1 (en) | 2007-09-19 | 2009-03-26 | Suntory Holdings Limited | Composition comprising sesamin component and vitamin b1 component |
JP2010248161A (en) * | 2009-04-20 | 2010-11-04 | Ito En Ltd | Anti-fatigue agent or physical fitness improver containing uridine |
JP2013511983A (en) * | 2009-11-25 | 2013-04-11 | ネステク ソシエテ アノニム | Nutritional composition comprising a high protein component and exogenous nucleotides |
US9609884B2 (en) | 2007-03-15 | 2017-04-04 | Suntory Holdings Limited | Anti-fatigue agent |
KR20180013981A (en) | 2015-06-01 | 2018-02-07 | 사이세이 파마 씨오., 엘티디. | Milk enzyme-treated water, its production method, composition and product |
US9895375B2 (en) | 2006-03-15 | 2018-02-20 | Suntory Holdings Limited | Compositions containing riboflavin and sesamin-class compounds |
KR20210003108A (en) | 2018-04-26 | 2021-01-11 | 제리아 신야쿠 고교 가부시키 가이샤 | Dipeptide and pharmaceutical composition containing the same |
CN114786502A (en) * | 2020-04-03 | 2022-07-22 | 三菱瓦斯化学株式会社 | Muscle-building agent |
-
1995
- 1995-11-08 JP JP28978195A patent/JP4526047B2/en not_active Expired - Fee Related
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2782270A1 (en) * | 1998-08-12 | 2000-02-18 | Michel Seman | Use of adenosine and adenylic nucleotides to improve muscular effort in sports and in immobilized and bedridden |
WO2000032202A1 (en) * | 1998-12-02 | 2000-06-08 | Philippe Gorny | Method for obtaining and using a combination of a purine and a nitrogen monoxide donor for preventing or treating sexual dysfunction |
FR2786699A1 (en) * | 1998-12-02 | 2000-06-09 | Philippe Gorny | MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS |
JP2003510059A (en) * | 1999-09-29 | 2003-03-18 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | Composition comprising casein protein and whey protein |
US9895375B2 (en) | 2006-03-15 | 2018-02-20 | Suntory Holdings Limited | Compositions containing riboflavin and sesamin-class compounds |
EP3342409A1 (en) | 2007-03-15 | 2018-07-04 | Suntory Holdings Limited | Anti-fatigue agent |
US9609884B2 (en) | 2007-03-15 | 2017-04-04 | Suntory Holdings Limited | Anti-fatigue agent |
WO2008149802A1 (en) | 2007-05-31 | 2008-12-11 | Suntory Holdings Limited | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient |
WO2009038095A1 (en) | 2007-09-19 | 2009-03-26 | Suntory Holdings Limited | Composition comprising sesamin component and vitamin b1 component |
JP2010248161A (en) * | 2009-04-20 | 2010-11-04 | Ito En Ltd | Anti-fatigue agent or physical fitness improver containing uridine |
JP2013511983A (en) * | 2009-11-25 | 2013-04-11 | ネステク ソシエテ アノニム | Nutritional composition comprising a high protein component and exogenous nucleotides |
KR20180013981A (en) | 2015-06-01 | 2018-02-07 | 사이세이 파마 씨오., 엘티디. | Milk enzyme-treated water, its production method, composition and product |
US11464835B2 (en) | 2015-06-01 | 2022-10-11 | Saisei Pharma Co., Ltd. | Enzyme-treated milk product, preparation method thereof, composition, and products |
KR20210003108A (en) | 2018-04-26 | 2021-01-11 | 제리아 신야쿠 고교 가부시키 가이샤 | Dipeptide and pharmaceutical composition containing the same |
CN114786502A (en) * | 2020-04-03 | 2022-07-22 | 三菱瓦斯化学株式会社 | Muscle-building agent |
Also Published As
Publication number | Publication date |
---|---|
JP4526047B2 (en) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100355420C (en) | Leucine-enriched nutritional compositions | |
JP4699901B2 (en) | Dietary additive with body fat metabolism function and combustion energy utilization function | |
EP1976397B1 (en) | Infant immunological formula | |
KR101075816B1 (en) | Total enteral nutritious composition | |
JP5315996B2 (en) | Total enteral nutrition composition | |
WO1999055326A1 (en) | Method of treatment of glutathione deficient mammals | |
CA2914811C (en) | Muscle preservation in overweight or obese adult during weight loss program | |
CZ24999A3 (en) | Pharmaceutical preparation | |
CN111972672A (en) | Composition with muscle increasing function and application thereof | |
CN104159592A (en) | Uses of casein compositions | |
JP4526047B2 (en) | Strength enhancer | |
US5849335A (en) | Composition and method for providing glutamine | |
JP4034370B2 (en) | Brain function improving agent and nutritional composition | |
JP2002065212A (en) | Food composition for strengthening muscle, and muscle- strengthening agent | |
JP2011157330A (en) | Motor function improving agent | |
JPH10327804A (en) | Nutrient composition containing nucleic acid-related substance, DHA, arachidonic acid and cholesterol | |
CN107529805A (en) | Composition comprising choline and its derivative, preparation method and use | |
JP2006515879A (en) | Method for improving nutrient utilization by mammals and compositions for use therein | |
JPH10262607A (en) | Nutrient composition for infant | |
JP2808281B2 (en) | Protein foods and physiological supplements | |
JP2005289861A (en) | Composition for promoting storage of glycogen | |
CN106036387A (en) | Super chenopodium quinoa willd nutritional packet for promoting growth of children | |
WO1999037167A2 (en) | Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby | |
JPH1028553A (en) | Immunostimulated liquid food | |
JP4307475B2 (en) | Infant nutrition composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060731 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060731 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070423 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070612 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100414 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100528 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130611 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130611 Year of fee payment: 3 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130611 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130611 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |